Status:
COMPLETED
Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Wellcome Trust
Conditions:
Stroke
Hemispatial Neglect
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To find out if spatial neglect following stroke and brain injury can be reduced using guanfacine, a drug that was shown to improve neglect in two stroke patients in a previous pilot study (Malhotra et...
Detailed Description
The current study has a double-blind crossover design where patients will receive a single 2mg dose of oral guanfacine and a single dose of placebo. They will receive one of these on Day 2 of the stud...
Eligibility Criteria
Inclusion
- Age 18 or more
- Greater than 2 weeks following stroke
- Ability to give consent
- Evidence of robust Visual Neglect when tested twice with cancellation tasks.
Exclusion
- Less than 2 weeks following stroke
- Concomitant illness that may affect interpretation of any findings
- Labile blood pressure following stroke
- Systolic BP less than 100 mmHg and / or diastolic less than 70 mmHg
- New antihypertensive medication started within last 3 weeks
- Patients with hepatic or renal dysfunction
- Patients receiving other medications known to potentiate guanfacine's antihypertensive and hypotensive effects or cause torsade de pointes, specifically antipsychotics (including sultopride, chlorpromazine, thioridazine, amisulpiride, sulpiride, haloperidol), and moxifloxacin, baclofen, verapamil, quinidine, hydroquinidine, dispyramide, amiodarone, dofetilide, ibutilide, sotalol, pimozide, bepridil, cisapride, diphemanil, erythromycin IV, halofantrine, pentamidine, sparfloxacin, vincamine, alfuzosin, prazosin, terazosin, tamsulosin, amifostine
- Patients with diagnosis of brain tumour
- Patients with weight less than 55kg
- Patients who are pregnant
- Mothers who are breast feeding
- Patients with severe coronary insufficiency or myocardial infarction in previous 6 months
- Cognitive impairment, dysphasia or dementia that prevents patient from giving informed consent
- Severe mental impairment or physical handicap following stroke that prevents patients from giving consent or performing basic (standard clinical) tests for neglect
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 28 2014
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00955253
Start Date
April 1 2010
End Date
March 28 2014
Last Update
January 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College Healthcare NHS Trust
London, United Kingdom, W6 8RF